TAK-715 is a potent p38 MAPK inhibitor. which displays potent inhibitory activity (inhibition of p38alpha, IC50 = 7.1 nM; LPS-stimulated release of TNF-alpha from THP-1, IC50 = 48 nM; LPS-induced TNF-alpha production in mice, 87.6% inhibition at 10 mg/kg, po) and no inhibitory activity for major CYPs, including CYP3A4. TAK-715 was selected as a clinical candidate and is now under clinical investigation for the treatment of RA.
p38 MAPK Inhibitors Related Products:
SB203580; Doramapimod; SB-202190; VX-702; PH-797804; Neflamapimod; R1487 HCl; SB239063; Losmapimod; Ralimetinib dimesylate